Precision oncology 2.0 in advanced colorectal cancer: resistance-state pharmacology and tumor ecosystem remodeling

Precision treatment in metastatic colorectal cancer (mCRC) has advanced through molecularly selected therapies, but pretreatment genotyping often fails to explain resistance that emerges during therapy. The clinical benefits of targeting resistance-related signaling are evident in BRAF V600E- and KRAS G12C-mutant disease. In the phase III BREAKWATER trial, encorafenib plus cetuximab and mFOLFOX6 extended median progression-free survival from 7.1 to 12.8 months in patients with BRAF V600E-mutant mCRC. Resistance can also be reassessed during the disease course. In the CHRONOS trial, circulating tumor DNA (ctDNA)-guided selection for panitumumab rechallenge yielded an objective response rate of 30% (8 of 27 patients). These advances contrast with the less mature evidence for targeting non-genetic resistance. LGR5-positive cancer stem cells can regenerate after selective depletion, while SMYD3 inhibition and ESM-1 blockade have shown activity mainly in experimental models. TGF-β inhibition has a strong biological rationale in immune-excluded CRC, but bintrafusp alfa showed limited activity in early clinical testing. This review examines the pharmacological basis of these differences and considers how resistance profiling might improve treatment selection. Transcriptomic and spatial analyses can identify adaptive tumor states that are difficult to resolve through genomic testing, although their ability to predict benefit from a matched intervention remains unproven. Building on the expression-guided Precision Oncology 2.0 concept, we propose a CRC-focused approach linking longitudinal molecular assessment to evidence-based treatment decisions and subsequent response evaluation. We identify prospective validation of ctDNA-guided treatment selection as a more immediate clinical priority than using unvalidated expression signatures to assign experimental therapies.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.3389/fphar.2026.1996651
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Precision oncology 2.0 in advanced colorectal cancer: resistance-state pharmacology and tumor ecosystem remodeling

Xudong Xie, Mingbing Xiao, Tong Wu, Xiaomin Lu et al.
2 links
Frontiers in Pharmacology
Colorectal Cancer Treatments and Studies
article

Precision oncology 2.0 in advanced colorectal cancer: resistance-state pharmacology and tumor ecosystem remodeling

Xudong Xie, Mingbing Xiao, Tong Wu, Xiaomin Lu, Mingxin Zhao, Xuebing Xu, Dandan Jin, Ran Zhao, Junpeng Zhao, Xiaogang Hu, Zhenkai Yang, Zihan Shi
article en

Abstract

Precision treatment in metastatic colorectal cancer (mCRC) has advanced through molecularly selected therapies, but pretreatment genotyping often fails to explain resistance that emerges during therapy. The clinical benefits of targeting resistance-related signaling are evident in BRAF V600E- and KRAS G12C-mutant disease. In the phase III BREAKWATER trial, encorafenib plus cetuximab and mFOLFOX6 extended median progression-free survival from 7.1 to 12.8 months in patients with BRAF V600E-mutant mCRC. Resistance can also be reassessed during the disease course. In the CHRONOS trial, circulating tumor DNA (ctDNA)-guided selection for panitumumab rechallenge yielded an objective response rate of 30% (8 of 27 patients). These advances contrast with the less mature evidence for targeting non-genetic resistance. LGR5-positive cancer stem cells can regenerate after selective depletion, while SMYD3 inhibition and ESM-1 blockade have shown activity mainly in experimental models. TGF-β inhibition has a strong biological rationale in immune-excluded CRC, but bintrafusp alfa showed limited activity in early clinical testing. This review examines the pharmacological basis of these differences and considers how resistance profiling might improve treatment selection. Transcriptomic and spatial analyses can identify adaptive tumor states that are difficult to resolve through genomic testing, although their ability to predict benefit from a matched intervention remains unproven. Building on the expression-guided Precision Oncology 2.0 concept, we propose a CRC-focused approach linking longitudinal molecular assessment to evidence-based treatment decisions and subsequent response evaluation. We identify prospective validation of ctDNA-guided treatment selection as a more immediate clinical priority than using unvalidated expression signatures to assign experimental therapies.

Frontiers in PharmacologyVol. 17
Nantong University (CN), Affiliated Hospital of Nantong University (CN)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon